Comprehensive Genomic Profiling in Cancer: How Low-VAF Variants Impact Treatment Decisions

Comprehensive genomic profiling (CGP) has become a cornerstone of precision oncology, enabling clinicians to identify actionable genetic alterations in tumors and match patients with targeted therapies. But, tumor tissue samples often contain mixtures of cancerous and normal cells, along with treatment-induced genetic changes, which can obscure the detection of clinically relevant mutations. Recent research highlights the importance of detecting low variant allele frequency (VAF) variants—those present in a minor fraction of tumor DNA—to improve treatment accuracy and avoid undertreatment in patients with metastatic solid tumors.

Understanding Variant Allele Frequency and Tumor Heterogeneity

Variant allele frequency refers to the proportion of DNA sequences carrying a specific mutation relative to the total number of sequences at that genomic location. In cancer, VAF is influenced by tumor purity, clonal evolution and prior therapies. Tumor tissues obtained in clinical settings frequently exhibit low purity and genetic heterogeneity, contributing to the presence of variants at low VAF (≤10%). These low-VAF alterations may be missed by less sensitive testing methods, potentially leading to incomplete genomic profiles and suboptimal treatment selection.

A large-scale analysis of 331,503 patients across 78 tumor types who underwent FDA-approved CGP targeting approximately 324 genes revealed that 29% of patients had at least one variant detected at VAF ≤10%, and 16% had variants at VAF ≤5%. Among commonly diagnosed cancers, the prevalence of low-VAF variants was particularly high in pancreatic (37%), non-small cell lung cancer (35%), colorectal (29%), and prostate (24%) tumors.

Clinical Significance of Low-VAF Variants

Both driver mutations—which promote tumor growth—and resistance-associated alterations can occur at low VAF. Notably, treatment resistance-related changes tend to have lower median VAF than driver mutations, but variants at VAF ≤5% include both categories. This underscores the need for highly sensitive genomic assays capable of detecting low-frequency variants, as they may represent emerging resistance mechanisms or minor clonal populations with therapeutic implications.

Failure to detect these low-VAF alterations can result in undertreatment, where patients do not receive therapies targeting identifiable molecular drivers or resistance pathways. Such gaps in profiling are likely to contribute to worse clinical outcomes, especially in advanced cancers where treatment options are limited and resistance develops rapidly.

The Role of Comprehensive Genomic Profiling in Clinical Practice

View this post on Instagram about Comprehensive, Genomic

CGP panels used in routine clinical care are designed to detect a broad spectrum of genomic alterations, including single nucleotide variants, insertions and deletions, copy number changes, and rearrangements. By capturing low-VAF variants, these tests enhance the ability to identify molecular subtypes, predict prognosis, uncover markers of therapeutic response, and elucidate the functional impact of somatic mutations. This information supports the selection of tumor-agnostic and biomarker-driven therapies, including those approved based on specific genetic alterations regardless of cancer type.

Real-world evidence suggests that CGP improves the applicability of precision oncology in metastatic solid tumors by expanding the range of actionable findings. However, challenges remain in ensuring equitable access, interpreting complex genomic data, and integrating results into timely treatment decisions.

Improving Outcomes Through Sensitive Genomic Detection

To maximize the benefit of CGP, laboratories and clinicians must prioritize assays with sufficient sensitivity to detect variants at low VAF. This includes optimizing sequencing depth, employing advanced bioinformatics tools for variant calling, and validating assays against reference standards. Combining tissue-based CGP with liquid biopsy approaches—such as circulating tumor DNA (ctDNA) analysis—may help capture spatial and temporal heterogeneity, particularly when tumor biopsies are infeasible or nondiagnostic.

Ongoing efforts to standardize reporting, improve data sharing, and integrate genomic findings with clinical and outcomes data will further strengthen the utility of CGP in guiding personalized cancer care.

Key Takeaways

• Tumor tissue samples often have low purity and genetic heterogeneity, leading to variants at low variant allele frequency (VAF).
• In a pan-cancer analysis of over 330,000 patients, 29% had at least one variant at VAF ≤10%, with higher rates in pancreatic, lung, colorectal, and prostate cancers.
• Low-VAF variants include both driver mutations and treatment resistance alterations, which may be missed by less sensitive tests.
• Undertreatment due to incomplete genomic profiling is likely to result in worse outcomes, particularly in metastatic solid tumors.
• Comprehensive genomic profiling capable of detecting low-VAF variants improves the identification of actionable alterations and supports precision oncology.
• Sensitive assays, combined with complementary approaches like ctDNA testing, are essential for capturing the full genomic landscape of tumors.

Frequently Asked Questions

What is variant allele frequency (VAF) in cancer genomics?

Variant allele frequency measures the proportion of DNA reads containing a specific mutation compared to the total number of reads at that locus. In tumors, VAF reflects the fraction of cancer cells harboring the alteration and is affected by tumor purity and clonal composition.

Why are low-VAF variants important in cancer treatment?

Low-VAF variants can represent clinically significant drivers of tumor growth or emerging resistance mechanisms. Detecting them ensures a more complete genomic profile, reducing the risk of undertreatment and enabling better-informed therapy decisions.

How does comprehensive genomic profiling detect low-VAF variants?

FDA-approved CGP tests use deep sequencing and advanced bioinformatics to identify variants present in as little as 1–5% of tumor DNA, depending on the assay’s sensitivity and tumor purity.

Which cancer types indicate the highest prevalence of low-VAF variants?

In the studied cohort, pancreatic cancer (37%), non-small cell lung cancer (35%), colorectal cancer (29%), and prostate cancer (24%) had the highest proportions of patients with at least one variant detected at VAF ≤10%.

Can low-VAF variants be detected in blood-based tests?

Yes, circulating tumor DNA (ctDNA) assays can detect low-VAF variants and may complement tissue-based profiling, especially when tissue samples are limited or heterogeneous.